Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody.

UNLABELLED Monoclonal antibodies (mAbs) labeled with alpha-emitting radionuclides such as (211)At, (212)Bi, (213)Bi, and (212)Pb (which decays by beta-emission to its alpha-emitting daughter, (212)Bi) are being evaluated for their potential applications for cancer therapy. The fate of these radionuclides after cells are targeted with mAbs is important in terms of dosimetry and tumor detection. METHODS In this study, we attached various radionuclides that result in alpha-emissions to T101, a rapidly internalizing anti-CD5 mAb. We then evaluated the catabolism and cellular retention and compared them with those of (125)I- and (111)In-labeled T101. T101 was labeled with (211)At, (125)I, (205,6)Bi, (111)In, and (203)Pb. CD5 antigen-positive cells, peripheral blood mononuclear cells (PBMNC), and MOLT-4 leukemia cells were used. The labeled T101 was incubated with the cells for 1 h at 4 degrees C for surface labeling. Unbound activity was removed and 1 mL medium added. The cells were then incubated at 37 degrees C for 0, 1, 2, 4, 8, and 24 h. The activity on the cell surface that internalized and the activity on the cell surface remaining in the supernatant were determined. The protein in the supernatant was further precipitated by methanol for determining protein-bound and non-protein-bound radioactivity. Sites of internal cellular localization of radioactivity were determined by Percoll gradient centrifugation. RESULTS All radiolabeled antibodies bound to the cells were internalized rapidly. After internalization, (205,6)Bi, (203)Pb, and (111)In radiolabels were retained in the cell, with little decrease of cell-associated radioactivity. However, (211)At and (125)I were released from cells rapidly ((211)At < (125)I) and most of the radioactivity in the supernatant was in a non-protein-bound form. Intracellular distribution of radioactivity revealed a transit of the radiolabel from the cell surface to the lysosome. The catabolism patterns of MOLT-4 cells and PBMNC were similar. CONCLUSION (211)At catabolism and release from cells were somewhat similar to that of (125)I, whereas (205,6)Bi and (203)Pb showed prolonged cell retention similar to that of (111)In. These catabolism differences may be important in the selection of alpha-radionuclides for radioimmunotherapy.

[1]  S. Mirzadeh,et al.  In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.

[2]  M. J. Mattes,et al.  Limitations in the use of low pH extraction to distinguish internalized from cell surface-bound radiolabeled antibody. , 2000, Nuclear medicine and biology.

[3]  L. Chappell,et al.  Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. , 2000, Nuclear medicine and biology.

[4]  Y. Erdi,et al.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  D. Bigner,et al.  Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate. , 1999, Nuclear medicine and biology.

[6]  T. Waldmann,et al.  Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  D. Scheinberg,et al.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  G. Griffiths,et al.  Intracellular processing of 99Tcm-antibody conjugates. , 1998, Nuclear medicine communications.

[9]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[10]  M. Brechbiel,et al.  In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand , 1998, European Journal of Nuclear Medicine.

[11]  G. Henriksen,et al.  ISOLATION OF CYCLOTRON PRODUCED 205BI, 206BI AND 203PB USING A LEAD-SELECTIVE EXTRACTION CHROMATOGRAPHIC RESIN , 1998 .

[12]  T. Waldmann,et al.  Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. , 1998, Nuclear medicine and biology.

[13]  T. Waldmann,et al.  Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  D. Goldenberg,et al.  The advantage of residualizing radiolabels for targeting B‐cell lymphomas with a radiolabeled anti‐CD22 monoclonal antibody , 1997, International journal of cancer.

[15]  L. Holder Principles of Nuclear Medicine. 2nd ed , 1996 .

[16]  I. Bernstein,et al.  Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.

[17]  D. Bigner,et al.  Radioimmunotherapy with α-Particle Emitting Radioimmunoconjugates , 1996 .

[18]  D. Bigner,et al.  Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. , 1996, Acta oncologica.

[19]  M J Welch,et al.  Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. , 1995, Cancer research.

[20]  D. Goldenberg,et al.  Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. , 1995, Cancer research.

[21]  Zsolt Szabo,et al.  Principles of Nuclear Medicine , 1995 .

[22]  G. Griffiths,et al.  The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  I. Pastan,et al.  Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Welch,et al.  Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  I. Pastan,et al.  Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. , 1993, Cancer research.

[26]  S. Larson,et al.  Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. , 1993, Acta oncologica.

[27]  D. Goldenberg,et al.  The fate of antibodies bound to the surface of tumor cells in vitro. , 1992, Cancer research.

[28]  S. Anderson,et al.  Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. , 1991, Cellular immunology.

[29]  S. Larson,et al.  Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[30]  C. Coleman,et al.  Alpha particle radio-immunotherapy: animal models and clinical prospects. , 1989, International journal of radiation oncology, biology, physics.

[31]  A. Chang,et al.  Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  J. Mulshine,et al.  Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  M. Lagunas-Solar,et al.  Cyclotron production of no-carrier-added 206Bi (6.24 d) and 205Bi (15.31 d) as tracers for biological studies and for the development of alpha-emitting radiotherapeutic agents. , 1987, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[34]  R. Dillman,et al.  Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. , 1986, Journal of biological response modifiers.

[35]  W. Pardridge,et al.  Rapid Sequestration and Degradation of Somatostatin Analogues by Isolated Brain Microvessels , 1985, Journal of neurochemistry.

[36]  R. Dillman,et al.  Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. , 1984, Cancer research.

[37]  R. Schroff,et al.  Enhancing effects of monocytes on modulation of a lymphocyte membrane antigen. , 1984, Journal of immunology.

[38]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[39]  I. Royston,et al.  Alterations in cell surface phenotype of T- and B-cell chronic lymphocytic leukemia cells following in vitro differentiation by phorbol ester. , 1984, Journal of the National Cancer Institute.

[40]  I. Royston,et al.  Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. , 1980, Journal of immunology.

[41]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[42]  F. Greenwood,et al.  Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.